Treatment of hepatitis C virus infection in the future

Clinical and Translational Medicine

Table 4 New standard of care treatment with other drugs (second-generation DAAs) chronic hepatitis C patients

References	G	Number of patients	Naïve or re-treatment	Formula of therapy, and duration of treatment (weeks)	SVR rates (%)	Notes
[48, 49]	G1	78	Naïve	TMC435 12 W peginterferon/ribavirin RGT	82.1	TMC435 (simeprevir) 75 mg daily
		75		TMC435 24 W peginterferon/ribavirin RGT	74.7	TMC435 (simeprevir) 75 mg daily
		77		TMC435 12 W peginterferon/ribavirin RGT	80.5	TMC435 150 mg daily
		79		TMC435 24 W peginterferon/ribavirin RGT	86.1	TMC435 150 mg daily
		77		Placebo	64.9
[48, 50]	G1	27	Relapsers	PR PR48	37
		79		TMC435 100 mg PR48	85
		79		TMC435 150 mg PR48	85
		23	Partial responders	PR PR48	9
		68		TMC435 100 mg PR48	57
		69		TMC435 150 mg PR48	75
		16	Null responders	PR PR48	19
		50		TMC435 100 mg PR48	46
		51		TMC435 150 mg PR48	51
[55]	G1	12		3 mg daclatasvir PR48	42	Treatment-naïve or less than 4 wks of exposure to ribavirin or interferon-based therapy
		12		10 mg daclatasvir PR48	83
		12		60 mg daclatasvir PR48	83
		12		Placebo PR48	25